OR WAIT null SECS
April 05, 2018
The European approval marks the first approval for a biosimilar in that region resulting from the companies’ joint portfolio.
Fujifilm acquires cell culture media companies Irvine Scientific Sales Company and IS Japan.
April 03, 2018
The agency has accepted AstraZeneca’s biologics license application for an investigational leukemia drug candidate and granted it priority review.
Pfizer transfers CAR-T assets to Allogene Therapeutics under a new alliance to further develop immuno-oncology therapeutics.
April 02, 2018
Access to multiple analytical techniques is essential for fully characterizing complex protein formulations.
The high viscosity of highly concentrated monoclonal antibody formulations not only presents processing and storage difficulties, but also formulation and delivery challenges.
Researchers at MIT have discovered a new set of compounds that do not elicit a foreign body response when implanted. These biomaterials permit the development of a new category of treatment with the ability to deliver therapeutics either at a constant rate or under programmable conditions by using implantable cells as protein factories.
March 29, 2018
The companies will co-develop and co-promote a CAR T cell therapy in the United States.
Novartis’ Sandoz is seeking approval of its biosimilar referencing Johnson & Johnson’s Remicade (infliximab) for all of Remicade’s indications across gastroenterology, rheumatology, and dermatology.
EMA has recommended approval of the biosimilar for the same indications as Roche’s Herceptin (trastuzumab).